Display options
Cite
Hagmann R, Hess V, Zippelius A, et al. Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. J Cancer. 2015;6(11):1148-54doi: 10.7150/jca.13080.
Hagmann, R., Hess, V., Zippelius, A., & Rothschild, S. I. (2015). Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. Journal of Cancer, 6(11), 1148-54. https://doi.org/10.7150/jca.13080
Hagmann, Raphael, et al. "Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience." Journal of Cancer vol. 6,11 (2015): 1148-54. doi: https://doi.org/10.7150/jca.13080
Hagmann R, Hess V, Zippelius A, Rothschild SI. Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. J Cancer. 2015 Sep 15;6(11):1148-54. doi: 10.7150/jca.13080. eCollection 2015. PMID: 26516363; PMCID: PMC4615351.
Copy Download .nbib Format: NLM
Share it on

J Cancer. 2015 Sep 15;6(11):1148-54. doi: 10.7150/jca.13080. eCollection 2015.

Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience.

Journal of Cancer

Raphael Hagmann, Viviane Hess, Alfred Zippelius, Sacha I Rothschild

Affiliations

  1. 1. Department Internal Medicine, Medical Oncology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
  2. 1. Department Internal Medicine, Medical Oncology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland ; 2. Lung Tumor Center, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.

PMID: 26516363 PMCID: PMC4615351 DOI: 10.7150/jca.13080

Abstract

BACKGROUND: Randomized trials established topotecan and the combination of adriamycin, cyclophosphamide and vincristine (ACO) as second-line therapy options for small-cell lung cancer. We retrospectively evaluated the outcome of SCLC patients undergoing second-line chemotherapy.

PATIENTS AND METHODS: 92 consecutive patients with a diagnosis of SCLC between 2000 and 2010 were analyzed.

RESULTS: 86 patients (93.5%) were evaluable for outcome analysis. All patients diagnosed with limited disease (LD) SCLC received platinum-based chemotherapy as first-line treatment. 69 patients (98.6%) diagnosed with extensive disease (ED) SCLC received first-line palliative chemotherapy. In the total cohort, the median overall survival (OS) was 10.3 months (19.2 months and 9.2 months for LD-SCLC and ED-SCLC, respectively). 42 patients received second-line therapy (ACO in 47.6% and topotecan in 31.0% of patients, respectively). Eight patients (19.0%) were re-challenged with platinum/etoposide. Neither the overall response rate (52.9% vs. 22.2%; p=0.128) nor progression-free survival (2.4 vs. 2.4 months; p=0.794) or OS (5.5 vs. 5.0 months; p=0.997) were significantly different between ACO and topotecan. ACO-treated patients showed a trend towards a longer duration of inpatient care.

CONCLUSION: We showed similar outcomes as reported in clinical trials. Second-line combination chemotherapy with ACO did not show superiority to intravenous topotecan, but was associated with a clinically relevant longer hospitalization time.

Keywords: ACO; Small cell lung cancer; chemotherapy; second-line therapy; topotecan

References

  1. J Clin Oncol. 2006 Dec 1;24(34):5441-7 - PubMed
  2. J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 - PubMed
  3. J Thorac Oncol. 2012 May;7(5):866-72 - PubMed
  4. J Thorac Oncol. 2007 Aug;2(8):706-14 - PubMed
  5. N Engl J Med. 2008 Sep 25;359(13):1367-80 - PubMed
  6. Lung Cancer. 2007 Jul;57(1):84-8 - PubMed
  7. Ann Oncol. 2013 Jan;24(1):75-83 - PubMed
  8. JAMA. 1992 Nov 4;268(17):2420-5 - PubMed
  9. Oncology (Williston Park). 1998 May;12(5):647-58; discussion 661-3 - PubMed
  10. Semin Surg Oncol. 2000 Mar;18(2):106-15 - PubMed
  11. Eur J Cancer Clin Oncol. 1987 Sep;23(9):1409-11 - PubMed
  12. J Clin Oncol. 1999 Feb;17(2):658-67 - PubMed
  13. Lung Cancer. 2004 Jul;45(1):105-17 - PubMed
  14. Eur J Cancer Clin Oncol. 1987 Nov;23(11):1697-9 - PubMed
  15. Crit Rev Oncol Hematol. 2014 Sep;91(3):257-70 - PubMed
  16. Can Med Assoc J. 1979 Nov 3;121(9):1193-254 - PubMed
  17. J Thorac Oncol. 2007 Apr;2(4):348-54 - PubMed
  18. J Clin Oncol. 2007 May 20;25(15):2086-92 - PubMed
  19. Lung Cancer. 2014 May;84(2):168-74 - PubMed
  20. J Clin Oncol. 1997 May;15(5):2090-6 - PubMed

Publication Types